Drugs / COR-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04674566 | Apr 2021 → Oct 2022 | COVID-19 | Corat Therapeutics Gmbh | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2021-06-22 | Corat Therapeutics Gmbh | Results CORAT antibody COR-101 binds and inhibits all B.1.617 SARS-CoV-2 variants, including the fast proliferating “delta” variant corat-therapeutics.com ↗
Our laboratory tests indicate that COR-101 recognizes the particularly aggressive new „delta” variant B.1.617.2, which is rapidly replacing the “alpha” variant B.1.1.7 |
| 2020-12-18 | Corat Therapeutics Gmbh | Results Human SARS-CoV-2 neutralizing antibody COR-101 demonstrates high efficacy in a COVID-19 animal model and is ready to be used in clinical studies to treat COVID-19 patients corat-therapeutics.com ↗
It induced recovery of SARS-CoV-2 infected hamsters within two days. |
| 2020-12-04 | Corat Therapeutics Gmbh | Results How human antibody COR-101 neutralizes the coronavirus SARS-CoV-2 corat-therapeutics.com ↗ |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-06-22 | Corat Therapeutics Gmbh | CORAT antibody COR-101 binds and inhibits all B.1.617 SARS-CoV-2 variants, including the fast proliferating “delta” variant corat-therapeutics.com ↗ |
| 2020-12-18 | Corat Therapeutics Gmbh | Human SARS-CoV-2 neutralizing antibody COR-101 demonstrates high efficacy in a COVID-19 animal model and is ready to be used in clinical studies to treat COVID-19 patients corat-therapeutics.com ↗ |
| 2020-12-04 | Corat Therapeutics Gmbh | How human antibody COR-101 neutralizes the coronavirus SARS-CoV-2 corat-therapeutics.com ↗ |
| 2020-11-15 | Corat Therapeutics Gmbh | CORAT lead product COR-101 ready for clinical trials corat-therapeutics.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | COR-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04674566 ↗ |
| Modality | Monoclonal antibody | “COR-101, a novel mAb with a silenced Fc region designed to minimize antibody-dependent enhancement” PMID 41654452 ↗ Feb 2026 |
| Route | Intravenous | “Administered intravenously (IV) single dose” NCT04674566 ↗ |